Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis

Acta Dermato-Venereologica

Volumn 91, Issue 4, 2011, Pages 478-479

  Elmholdt, Tina Rask ^a   Pedersen, Michael ^a   Jørgensen, Bettina ^a   Ramsing, Mette ^a   Olesen, Anne Braae ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PREDNISOLONE;

ADULT; CASE REPORT; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JOINT CONTRACTURE; JOINT FUNCTION; LETTER; LOW DRUG DOSE; MALE; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; SCLERODERMA; SIDE EFFECT; SKIN INFLAMMATION; SKINFOLD; VOMITING; WALKING;

ADULT; HUMANS; JOINTS; MALE; NEPHROGENIC FIBROSING DERMOPATHY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANGE OF MOTION, ARTICULAR; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958789584     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1085     Document Type: Letter

References (14)

1. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008; 67 Suppl 3: 366-369.
2. Abraham JL, Tharkral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008; 158: 273-280.
3. High WA, Ranville JF, Brown M, Punshon T, Lanzirotti A, Jackson BP. Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron X-ray fuorescence spectroscopy. J Am Acad Dermatol 2010; 62: 38-44.
4. Koreishi AF, Nazarian RM, Saenz AJ, Klepeis VE, McDonald AG, Farris AB, et al. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med 2009; 133: 1943-1948.
5. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008; 73: 1413-1418.
6. Nagai Y, Hasegawa M, Shinmi K, Kishi C, Tsushima Y, Endo K, et al. Nephrogenic systemic fibrosis with multiple calcifcation and osseous metaplasia. Acta Derm Venereol 2008; 88: 597-600.
7. Panesar M, Banerjee S, Barone GW. Clinical improvement of nephrogenic systemic fbrosis after kidney transplantation. Clin Transplant 2008; 22: 803-808.
8. Leung N, Shaikh A, Cosio FG, Griffn MD, Textor SC, Gloor JM, et al. The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. Am J Transplant 2010; 10: 558-562.
9. Kay J, High WA. Imatinib mesylate treatment of neph-rogenic systemic fibrosis. Arthritis Rheum 2008; 58: 2543-2548.
10. Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly 2010; 140: w13050.
11. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profbroge-nic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-1316.
12. Jiménez SA, Artlett CM, Sandorf N, Derk C, Latinis K, Sawaya H, et al. Dialysis-associated systemic fibrosis (nephro genic fibrosing dermopathy): study of infammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004; 50: 2660-2666.
13. van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008; 58: 2549-2552.
14. Sfkakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008; 47: 735-737.